Phase III trial of BXCL 501 meets endpoints in patients with agitation and schizophrenia and bipolar disorder.- BioXcel Therapeutics
BioXcel Therapeutics announced that BXCL 501 (sublingual dexmedetomidine), met the primary and secondary endpoints of SERENITY I and SERENITY II, demonstrating a robust treatment effect in the trials… read more.